Mild To Moderate Erectile Dysfunction Study

Phase 4CompletedNCT00137072

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.355 enrolled

Overview

Safety/Efficacy of 100-mg Viagra at 8 hours post dose in men with mild to moderate erectile dysfunction

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

355

Conditions

Impotence

Interventions

Viagra (Sildenafil Citrate) 100 mgDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men 18-70 years of age * Documented clinical diagnosis of erectile dysfunction of at least 3 months duration. Exclusion Criteria: * Subjects with penile implants * Subjects with a known history of retinitis pigmentosa. * Subjects, due to the requirement of 100 mg dosage, who are receiving concomitant treatment with the potent CYP3A4 inhibitor ritonavir.

Locations (33)

Outcomes

Primary Outcomes

To determine the proportion of sexual intercourses that are successful in men with mild to moderate ED 8 hrs after a dose of Viagra.

Secondary Outcomes

To determine the proportion of sexual intercourses that are successful in men with mild to moderate ED 12 hrs after a dose of Viagra. Other questionnaires such as SEP, IIEF.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Homewood, Alabama, United States

Pfizer Investigational Site

Hoover, Alabama, United States

Pfizer Investigational Site

Huntsville, Alabama, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Beverly Hills, California, United States

Pfizer Investigational Site

La Mesa, California, United States

Pfizer Investigational Site

Newport Beach, California, United States

Pfizer Investigational Site

San Diego, California, United States

Pfizer Investigational Site

Aurora, Colorado, United States

...and 23 more locations